Zacks Investment Research upgraded shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) from a sell rating to a hold rating in a research note published on Wednesday.

According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “

A number of other analysts also recently weighed in on the stock. Piper Jaffray Companies reissued an overweight rating and set a $48.00 price target on shares of Reata Pharmaceuticals in a research report on Monday, March 6th. Stifel Nicolaus assumed coverage on shares of Reata Pharmaceuticals in a research report on Wednesday, February 22nd. They set a buy rating and a $38.00 price target for the company. Robert W. Baird assumed coverage on shares of Reata Pharmaceuticals in a research report on Tuesday, January 24th. They set an outperform rating and a $43.00 price target for the company. Finally, Cowen and Company reissued a buy rating on shares of Reata Pharmaceuticals in a research report on Thursday, December 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $36.50.

Reata Pharmaceuticals (NASDAQ:RETA) opened at 27.33 on Wednesday. The stock’s market cap is $610.66 million. The firm’s 50-day moving average is $25.32 and its 200-day moving average is $24.97. Reata Pharmaceuticals has a 12 month low of $11.03 and a 12 month high of $41.60.

Your IP Address:

In other Reata Pharmaceuticals news, Director Cpmg Inc acquired 9,392 shares of the firm’s stock in a transaction on Friday, December 30th. The stock was purchased at an average price of $21.72 per share, with a total value of $203,994.24. Following the completion of the acquisition, the director now directly owns 113 shares in the company, valued at approximately $2,454.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 62.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Strs Ohio increased its position in Reata Pharmaceuticals by 257.9% in the third quarter. Strs Ohio now owns 6,800 shares of the company’s stock worth $179,000 after buying an additional 4,900 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Reata Pharmaceuticals during the fourth quarter worth approximately $216,000. Interwest Venture Management Co. acquired a new position in Reata Pharmaceuticals during the fourth quarter worth approximately $285,000. Bessemer Group Inc. acquired a new position in Reata Pharmaceuticals during the fourth quarter worth approximately $380,000. Finally, University of Texas Investment Managment Co. increased its position in Reata Pharmaceuticals by 2,367.0% in the third quarter. University of Texas Investment Managment Co. now owns 28,593 shares of the company’s stock worth $754,000 after buying an additional 27,434 shares in the last quarter. 64.18% of the stock is owned by hedge funds and other institutional investors.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

5 Day Chart for NASDAQ:RETA

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reata Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.